Actual prescribing guidelines will only be available once the medication is approved
Keywords: GLP-1 receptor agonists, obesity, weight loss, non-diabetic patients, cardiovascular outcomes, cost-effectiveness Introduction Obesity is a chronic disease with high prevalence and associated comorbidities, making it a growing global concern [7] [8]
Day 23: Assigned to a Provider After payment, it took about 24 hours before I was matched with a licensed provider
A patient may have excess weight, high blood pressure, insulin resistance, high triglycerides, low HDL cholesterol, inflammation, fatty liver risk, poor sleep, and low muscle mass at the same time
GLP-1s help lower your set point by decreasing hunger, increasing satiety, and regulating hormones
It is estimated that 8.4 million individuals are living with the disease worldwide, and this is expected to increase [1]